|
|
Vaccine Detail
|
Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007147
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- KLK3
gene engineering:
- Type: Recombinant protein preparation
- Description: (Hannu et al., 2014)
- Detailed Gene Information: Click Here.
- Description: This is for Prostate Cancer (NCT02111577).A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the prostate tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against prostate cancer cells expressing prostate tumor cell-specific antigens, which may result in prostate tumor cell lysis (Hannu et al., 2014; NCIT_C115106).
|
| Host Response |
|
|
| References |
Hannu et al., 2014: Hannu K, Johanna M, Ulf-Håkan S. KLK-targeted Therapies for Prostate Cancer. EJIFCC. 2014; 25(2); 207-218. [PubMed: 27683469].
NCIT_C115106: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115106]
NCT02111577: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE) [https://clinicaltrials.gov/ct2/show/NCT02111577]
|
|
